Elon Musk’s electric-car maker is driving faster just to stay in place. The firm’s gross auto margin declined in the latest quarter even as it ramped up output. Tesla now has a bigger cash cushion, but as Antony Currie explains, the road to profitabili…
Facebook may have gotten off lightly with a $5 bln fine from the FTC for mishandling users’ data, explain Jennifer Saba and Antony Currie. But Silicon Valley’s big four are facing ever more regulatory scrutiny. As Microsoft and AT&T know, that can take…
The iPhone maker is mulling a bid for Intel’s modem-chip unit. Making more components in-house could help boss Tim Cook boost margins. Even better, explains Robert Cyran, it could reduce the company’s royalty payments to Qualcomm, a big bone of content…
Equifax is paying some $800 mln to resolve its 2017 breach of financial information. Yet as Robert Cyran explains, that includes less than $3 in compensation for each of the nearly 150 million Americans affected – a sum that does little to encourage ti…
China’s top ride-hailing app wants to raise up to $2 bln, according to a media report. Robyn Mak and Clara Ferreira Marques discuss the challenges it faces at home and abroad, and why after disappointing debuts from rivals Uber and Lyft, investors will…
Morgan Stanley followed Wall Street peers with a glum quarter in trading, but wealth management cushioned the blow. That’s one of James Gorman’s biggest achievements in his near-decade as CEO, Antony Currie argues. If only shareholders had more than mi…
Amazon.com is offering $10 to consumers who let it track their web browsing. It’s a cheap way to boost the e-commerce giant’s clout, but as Robert Cyran explains, it also underscores the anti-competitive concerns the U.S. Congress and European regulato…
Wall Street earnings are in full swing. Jennifer Saba and Antony Currie explain why Goldman Sachs boss David Solomon may be thankful for the lumpy businesses he’s trying to downplay, how Wells Fargo’s cost cutting may aid its CEO search – and how JPMor…
The biotech giant is spending $5.1 billion on Belgian outfit Galapagos but won’t take control. That, says Robert Cyran, means Gilead can profit from the smaller drugmaker’s successes, while limiting the risk. It’s a smart move, as both Roche and Sanofi…
Fewer venture deals in the mainland, lacklustre initial public offerings and a trade war all clouded the outlook at Hong Kong’s annual Rise technology conference. There could still be good news for investors and newer markets, as Alec Macfarlane explai…